Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 74 clinical trials
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.

metastatic melanoma
platelet count
liver metastasis
nivolumab
blood count
  • 0 views
  • 10 Jul, 2022
  • 1 location
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.

metastasis
measurable disease
mucosal melanoma
serum pregnancy test
oophorectomy
  • 6 views
  • 11 Mar, 2022
  • 3 locations
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Currently, standard treatment options available for Stage III melanoma include locoregional management (i.e. surgery) or systemic treatment (adjuvant to surgery or primarily in the case of unresectable disease). Adjuvant treatment options have shown major improvements in overall survival (OS) and relapse free survival (RFS) in resected stage III or IV …

metastatic melanoma
metastasis
measurable disease
treatment regimen
nivolumab
  • 0 views
  • 23 Mar, 2022
  • 1 location
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

  • 0 views
  • 23 Mar, 2022
  • 1 location
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib …

  • 0 views
  • 28 Dec, 2021
  • 1 location
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer …

cancer
metastatic melanoma
metastasis
liver metastasis
measurable disease
  • 13 views
  • 22 Mar, 2022
  • 3 locations
FMT to Convert Response to Immunotherapy

In this study the aim is to investigate whether transfer of the microbiota of either responder or non-responder patients via fecal microbiotica transplantation (FMT) can convert the response to immunotherapy in immune checkpoint inhibitors (ICI) refractory metastatic melanoma patients. This is a randomized double-blind intervention phase Ib/IIa trial in ICI …

  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.

  • 0 views
  • 27 Oct, 2022
  • 1 location
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

  • 3 views
  • 18 Jun, 2022
  • 1 location
A Phase 2, Multicentre, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

The purpose of this study is to find out if a new treatment cancer vaccine called SCIB1 can be used safely when added to either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma (skin cancer). The study will also look to see …

cancer
metastatic melanoma
measurable disease
ct scan
yervoy
  • 21 views
  • 24 Oct, 2022
  • 5 locations